$38.1 Million is the total value of venBio Partners L.P.'s 3 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals, Inc | $23,611,000 | -25.8% | 1,790,102 | 0.0% | 62.01% | +11.4% | ||
VRNA | Verona Pharma PLCsponsored ads | $8,444,000 | -22.9% | 875,000 | 0.0% | 22.18% | +15.8% | |
MNLO | Menlo Therapeutics Inc. | $6,022,000 | -58.2% | 1,461,552 | 0.0% | 15.82% | -37.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Apellis Pharmaceuticals, Inc | 5 | Q4 2018 | 77.1% |
Verona Pharma PLC | 5 | Q4 2018 | 22.2% |
Menlo Therapeutics Inc. | 4 | Q4 2018 | 33.9% |
Nabriva Therapeutics PLC | 3 | Q2 2018 | 12.6% |
View venBio Partners L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2019-02-14 |
13F-HR | 2018-11-14 |
13F-HR | 2018-08-14 |
13F-HR | 2018-04-25 |
13F-HR | 2018-04-25 |
View venBio Partners L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.